Mechanistic Overview
Both SARMs and anabolic steroids act through the androgen receptor (AR). The key pharmacological difference lies in what happens after AR binding:
- Anabolic steroids: Bind AR with high affinity; receptor conformation recruits coactivators uniformly; activates AR target genes similarly across muscle, bone, prostate, hair follicles, and other tissues
- Non-steroidal SARMs: Bind AR and induce a slightly different receptor conformation; tissue-specific coactivator differences lead to different gene expression patterns in different tissues — anabolic in muscle/bone, reduced androgenic activation in prostate/scalp
Full Comparison Table
| Property | Non-Steroidal SARMs | Anabolic Steroids (Testosterone) | Oral Anabolic Steroids (17α-AA) |
|---|---|---|---|
| Chemical structure | Non-steroidal | Steroidal | Steroidal (17α-alkylated) |
| AR tissue selectivity | High (muscle > prostate) | Low (equal across tissues) | Low |
| 5α-reduction → DHT | None | Yes (prostate, skin) | Variable |
| Aromatization → E2 | None | Yes (gynecomastia risk at high doses) | Variable |
| HPTA suppression | Yes (dose-dependent) | Yes | Yes |
| Hepatotoxicity | Low (no 17α-AA) | Low (injectable) | High (17α-alkylation) |
| Prostate stimulation | Low (vs testosterone) | High (via DHT amplification) | Variable |
| Erythrocytosis (high Hct) | Low in clinical data | Yes (clinically relevant) | Yes |
| Oral bioavailability | High (90%+, most SARMs) | Low (requires injection or 17α-AA) | High (hepatotoxic) |
| Regulatory status (US) | Research chemicals (unscheduled) | Schedule III (controlled) | Schedule III (controlled) |
| Approved therapeutic use | None (investigational) | Yes (TRT, hypogonadism) | Limited (some oral formulations) |
Why SARMs Emerged as a Research Category
The SARM class was specifically designed to solve the testosterone problem: testosterone is therapeutically effective for muscle wasting, osteoporosis, and hypogonadism, but its clinical use is limited by:
- Prostate stimulation: BPH exacerbation and prostate cancer risk in older men
- Polycythemia: erythrocytosis (high hematocrit) from EPO stimulation
- Cardiovascular: lipid effects, particularly HDL reduction
- Virilization: DHT-driven effects in women
SARMs represent the hypothesis that tissue-selective AR agonism can achieve the anabolic benefits with a safer androgenic profile. The Phase II and Phase III clinical data for LGD-4033 and Ostarine support this hypothesis in terms of PSA and hepatic safety, though HPTA suppression and lipid effects remain research considerations.